Home › Retinopathy of Prematurity › NCT05558059
Imaging Retinal Vasculature in Infant Eyes
Elucidating Perifoveal Vasculature Development in Infants
Who can join
2 Months · All sexes
Full eligibility criteria
Inclusion Criteria: * Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian * Parent/Legal Guardian is able and willing to consent to study participation for the infant * Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age less than 34 6/7 weeks postmenstrual age at first visit Exclusion Criteria: * Participant or Parent/Legal Guardian unwilling or unable to provide consent * Infant has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract) * Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)
About the study
Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.
What is being tested
- Handheld Optical Coherence Tomography with OCT Angiography (device)
Sponsor: Duke University · Participants: 16 · Started: Oct 3, 2024
Contact the study team
- Xi Chen, MD · Phone: (919) 684-8434
- Michelle N McCall · Phone: (919) 684-0544
Official record on ClinicalTrials.gov — NCT05558059
Locations in the U.S.
| North Carolina | Duke University, Durham |
| Pennsylvania | University of Pennsylvania, Philadelphia (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.